Align Technology, Inc.
ALGN Healthcare Medical - Devices NASDAQ
$174.00
$-1.60 (-0.91%)
Open: $169.89 | High: $174.31 | Low: $168.01 | Prev Close: $175.60
Market Cap: $12.48B
Volume: 1.8M | Avg: 1.2M
Last updated: March 09, 2026 at 02:00 AMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 545
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 30.74 |
| P/B Ratio | 3.08 |
| P/S Ratio | 3.09 |
| EPS | $5.66 |
| Beta | 1.82 |
| Shares Outstanding | 71.75M |
| 52-Week High | $208.31 |
| 52-Week Low | $122.00 |
| SMA 50 | $173.81 |
| SMA 200 | $160.08 |
| Next Earnings | April 29, 2026 08:00 PM ET |
Financial Ratios
| Gross Margin | 67.3% |
| Operating Margin | 13.6% |
| Net Margin | 10.2% |
| ROE | 10.4% |
| ROA | 6.6% |
| Debt/Equity | 0.03 |
| Current Ratio | 1.36 |
| Quick Ratio | 1.24 |
Balance Sheet
| Total Assets | $6.23B |
| Total Liabilities | $2.18B |
| Total Equity | $4.05B |
|
|
|
| Cash | $1.08B |
| Total Debt | $114.45M |
| Net Debt | $-964,545,000 |
Income Statement
| Revenue | $4.03B |
| Gross Profit | $2.76B |
| Operating Income | $616.22M |
| Net Income | $410.35M |
|
|
|
| EBITDA | $765.87M |
| Revenue/Share | $56.29 |
Cash Flow
| Operating CF | $593.22M |
| CapEx | $102.44M |
| Free Cash Flow | $490.78M |
|
|
|
| Book Value/Share | $56.49 |
| Tangible Book/Share | $48.31 |
| Equity/Share | $56.49 |
Technical Indicators
| RSI (14) | 37.65 Neutral |
| MACD |
1.64
Signal: 3.97
|
| Volatility | 47.18% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | -5.86% |
| Sharpe Ratio | 0.13 Fair |
| Volatility (Ann.) | 54.84% High Risk |
| ALGN (1Y) | -5.86% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -18.9% |
Sector Comparison (Healthcare)
| Metric | ALGN | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 30.74 | 27.6 | 64% |
| P/B Ratio | 3.08 | -19.58 | 51% |
| ROE (%) | 10.45% | -9.49% | 40% |
| Net Margin (%) | 10.17% | 9.30% | 47% |
| Stock Score | 545 | 543.0 | 47% |
| 1Y Return (%) | -5.86 % | +8.42 % | 35% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALGN | $174.00 | $180.32 | $183.25 | $184.57 | $173.66 | $160.05 | 37.65 | 1.64 | 47.18% | 1240939 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the ALGN stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| ALGN | Align Technology (ALGN) is a Top-Ranked Value Stock: Should You Buy? | Neutral | zacks.com | Read More |
| ALGN | Align Technology, Inc. $ALGN Shares Acquired by Capital International Inc. CA | Neutral | defenseworld.net | Read More |
| ALGN | Align Technology, Inc. (ALGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript | Neutral | seekingalpha.com | Read More |
| ALGN | Are Medical Stocks Lagging Align Technology (ALGN) This Year? | Neutral | zacks.com | Read More |
| ALGN | Dynamic Technology Lab Private Ltd Purchases New Position in Align Technology, Inc. $ALGN | Neutral | defenseworld.net | Read More |
Recent Insider Trading
| Date | Insider | Position | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-02-20 | Morici John | officer: EVP, CHIEF FINANCIAL OFFICER | SELL | 2549 | $190.02 | $484361 |
| 2026-02-20 | Hockridge Stuart A | officer: EVP, GLOBAL HR | SELL | 1210 | $190.02 | $229924 |
| 2026-02-20 | Coletti Julie Ann | officer: EVP, CHIEF LEGAL & REGULATORY | SELL | 1718 | $190.02 | $326454 |
| 2026-02-20 | HOGAN JOSEPH M | director, officer: President and CEO | SELL | 16107 | $190.02 | $3060652 |
Company Information
Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.
| CEO | Joseph Hogan |
| Employees | 21200 |
| Country | US |
| IPO Date | 2001-01-30 |
| Exchange | NASDAQ |
| Website | https://www.aligntech.com |
| Sector | Healthcare |
| Industry | Medical - Devices |
Similar Stocks (Healthcare - Medical - Devices)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category